Harding et al. reported response rates in 27 patients with HCC treated with ICIs (including anti-PD-1 antibody monotherapy, anti-PD-L1 antibody monotherapy, anti-CTLA antibody monotherapy, and ICI-ICI). The gene discussed is CD274; the disease is hepatocellular carcinoma.